Merck (MRK) Dips More Than Broader Market: What You Should Know

In the latest close session, Merck (MRK) was down 1.28% at $118.10. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Elsewhere, the Dow saw an upswing of 0.11%, while the tech-heavy Nasdaq depreciated by 0.73%. Shares of the pharmaceutical company have depreciated by 3.38% over the course of the past month, outperforming the Medical sector's loss of 10.07%, and the S&P 500's loss of 7.34%.Analysts and investors alike will be keeping a close eye on the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to go public on April 30, 2026. The company is predicted to post an EPS of -$0.57, indicating a 125.68% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $16.01 billion, up 3.09% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.47 per share and revenue of $66.68 billion, indicating changes of -39.09% and +2.57%, respectively, compared to the previous year. Investors should also pay attention to any latest changes in analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.19% increase. Merck is holding a Zacks Rank of #3 (Hold) right now. In the context of valuation, Merck is at present trading with a Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 14.41, so one might conclude that Merck is trading at a premium comparatively. Meanwhile, MRK's PEG ratio is currently 2.18. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.18 at yesterday's closing price. The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow MRK in the coming trading sessions, be sure to utilize Zacks.com. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks